Evaluation of P53 and CK20 Immunohistochemical Markers in Comparison with Morphologic Findings in Low- and High-grade Urothelial Carcinomas.
CK20
Grade
P53
Urothelial carcinoma
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
12
2020
accepted:
13
01
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
ppublish
Résumé
Urothelial carcinoma is the seventh most common cancer in the world. The histological classification of papillary carcinoma is one of the most important determinants for its prognosis. Sometimes there is an overlap in the extent of the tumor, and the accurate microscopic diagnosis of the tumor is not always easy. The aim of this study was to evaluate P53 and CK20 immunohistochemical markers in comparison with morphologic findings in low- and high-grade urothelial carcinomas. For this descriptive study, urinary bladder samples were collected from 50 cancer patients who had undergone biopsy and surgery in Shohaday-e Tajrish Hospital of Tehran, Iran, during the years 2015-2016. P53 and CK20 were studied, and the demographic and histopathological characteristics of the tumor were also analysed. The mean age of patients enrolled in this study (48 males and 2 females) was 65.8±11.9. Twenty-five cases presented with low-grade and 25 cases presented with high-grade papillary urothelial carcinomas. Sensitivity, specificity, and positive and negative predictive values for P53 were 48%, 80%, 70.5%, and 60.6%, respectively, while the same values for CK20 were 44%, 92%, 84.6%, and 62.2%, respectively. Immunohistochemical results were also positively correlated with the extent of the tumor. Based on the results, P53 and CK20 may serve as specific markers for diagnosis of low- and high-grade papillary urothelial carcinoma but not sensitive. P53 and ck20 staining have also a high specificity as 80% and 92% and low sensitivity compared to the low and high morphology of papillary carcinoma, thus their positive and their staining intensity are valuable for diagnosis, but their negative results are not determinant.
Sections du résumé
BACKGROUND & OBJECTIVE
OBJECTIVE
Urothelial carcinoma is the seventh most common cancer in the world. The histological classification of papillary carcinoma is one of the most important determinants for its prognosis. Sometimes there is an overlap in the extent of the tumor, and the accurate microscopic diagnosis of the tumor is not always easy. The aim of this study was to evaluate P53 and CK20 immunohistochemical markers in comparison with morphologic findings in low- and high-grade urothelial carcinomas.
METHODS
METHODS
For this descriptive study, urinary bladder samples were collected from 50 cancer patients who had undergone biopsy and surgery in Shohaday-e Tajrish Hospital of Tehran, Iran, during the years 2015-2016. P53 and CK20 were studied, and the demographic and histopathological characteristics of the tumor were also analysed.
RESULTS
RESULTS
The mean age of patients enrolled in this study (48 males and 2 females) was 65.8±11.9. Twenty-five cases presented with low-grade and 25 cases presented with high-grade papillary urothelial carcinomas. Sensitivity, specificity, and positive and negative predictive values for P53 were 48%, 80%, 70.5%, and 60.6%, respectively, while the same values for CK20 were 44%, 92%, 84.6%, and 62.2%, respectively. Immunohistochemical results were also positively correlated with the extent of the tumor.
CONCLUSION
CONCLUSIONS
Based on the results, P53 and CK20 may serve as specific markers for diagnosis of low- and high-grade papillary urothelial carcinoma but not sensitive. P53 and ck20 staining have also a high specificity as 80% and 92% and low sensitivity compared to the low and high morphology of papillary carcinoma, thus their positive and their staining intensity are valuable for diagnosis, but their negative results are not determinant.
Identifiants
pubmed: 34306125
doi: 10.30699/IJP.2021.136330.2493
pmc: PMC8298052
doi:
Types de publication
Journal Article
Langues
eng
Pagination
297-303Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Urol Oncol. 2020 May;38(5):449-458
pubmed: 31740332
J Nippon Med Sch. 2004 Dec;71(6):379-83
pubmed: 15673958
J Cancer. 2017 Feb 5;8(3):323-331
pubmed: 28261332
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Curr Cancer Drug Targets. 2005 Feb;5(1):57-68
pubmed: 15720190
Cancer. 2007 Mar 15;109(6):1106-13
pubmed: 17311310
Am J Surg Pathol. 2001 Aug;25(8):1074-8
pubmed: 11474293
Bratisl Lek Listy. 2013;114(8):431-8
pubmed: 23944616
Iran J Pathol. 2021 Spring;16(2):154-161
pubmed: 33936226
Int J Urol. 2000 Dec;7(12):457-63
pubmed: 11168685
Virchows Arch. 2013 Oct;463(4):575-81
pubmed: 23913166
Eur Urol. 2014 Jan;65(1):218-26
pubmed: 22633802
Pathol Res Pract. 1997;193(11-12):767-75
pubmed: 9521509
Virchows Arch. 2008 Apr;452(4):353-62
pubmed: 18311491
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Surg Pathol. 2012 Jul;36(7):1081-6
pubmed: 22510761
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Urol J. 2016 Jun 28;13(3):2677-83
pubmed: 27351322
Patholog Res Int. 2017;2017:6794150
pubmed: 28210516
Hum Pathol. 2010 Feb;41(2):155-62
pubmed: 19762067
Arch Iran Med. 2010 Mar;13(2):143-6
pubmed: 20187669
Int Arch Med. 2014 Jul 26;7:36
pubmed: 25089155
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Transl Androl Urol. 2019 Feb;8(1):5-11
pubmed: 30976562
Iran J Pathol. 2021 Winter;16(1):69-74
pubmed: 33391383
Ann Intern Med. 2015 Dec 15;163(12):922-31
pubmed: 26501851
J Indian Med Assoc. 2012 Jun;110(6):393-6
pubmed: 23360043
Med J Islam Repub Iran. 2016 Jul 18;30:400
pubmed: 27579290
Virchows Arch. 2018 May;472(5):749-758
pubmed: 29654370
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Oncol Rep. 2002 Mar-Apr;9(2):253-9
pubmed: 11836589